1. P02.02.A Next-generation sequencing (NGS) for identifying actionable molecular alterations in newly diagnosed and recurrent IDHwt-glioblastoma (GBM) patients: a large mono institutional experience. (5th September 2022) Authors: Padovan, M; Maccari, M; Bosio, A; Vizzaccaro, S; Cestonaro, I; Corrà, M; Caccese, M; Cerretti, G; Fassan, M; Zagonel, V; Lombardi, G Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P11.20.A Correlation between thyroid function and regorafenib activity in recurrent IDH wild-type(IDHwt) glioblastoma(GBM) patients: a large monocentric study. (5th September 2022) Authors: Caccese, M; Padovan, M; Cerretti, G; Cavallin, F; Zagonel, V; Lombardi, G Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii60 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P14.19 Regorafenib in recurrent glioblastoma patients: a large real-life experience. (9th September 2021) Authors: Caccese, M; Cerretti, G; Padovan, M; Zagonel, V; Lombardi, G Journal: Neuro-oncology Issue: Volume 23: Supplement 2 (2021) Page Start: ii41 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P17.06.B Different dosage of bevacizumab treatment in recurrent IDHwt glioblastoma/IDHmut grade 4 astrocytoma and its impact on outcome. (5th September 2022) Authors: Bosio, A; Caccese, M; Padovan, M; Cerretti, G; Zagonel, V; Lombardi, G Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii90 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P17.07.A Metronomic temozolomide therapy in heavily pretreated patients with recurrent glioblastoma: a large mono-institutional retrospective study. (5th September 2022) Authors: Bosio, A; Padovan, M; Caccese, M; Cerretti, G; Zagonel, V; Lombardi, G Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii90 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P18.05.A Bevacizumab in atypical and anaplastic meningiomas: the BEMEN study. (5th September 2022) Authors: Cerretti, G; Bosio, A; Maccari, M; Padovan, M; Caccese, M; Zagonel, V; Lombardi, G Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii95 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. PL02.5.A The clinical significance of telomerase reverse transcriptase (TERT) promoter mutations, telomere length and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation status in newly diagnosed and recurrent IDHwildtype glioblastoma (GBM) patients (PTS): A large mono-institutional study. (9th September 2021) Authors: Lombardi, G; Giunco, S; Cavallin, F; Angelini, C; Caccese, M; Cerretti, G; De Bonis, P; De Rossi, A; Zagonel, V Journal: Neuro-oncology Issue: Volume 23: Supplement 2(2021) Page Start: ii1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗